Could 2 years of hormone therapy be enough for some breast cancers?
NCT ID NCT07153757
First seen Nov 01, 2025 · Last updated May 17, 2026 · Updated 32 times
Summary
This study looks at whether women with a certain type of early-stage, low-risk breast cancer can safely take hormone therapy for only 2 to 3 years instead of the usual longer period. About 2,900 participants will be randomly assigned to either the shorter or standard treatment. The goal is to see if the shorter treatment works just as well to prevent the cancer from coming back, while possibly causing fewer side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER EARLY STAGE BREAST CANCER (STAGE 1-3) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
270 Dongan Road, Fudan University Shanghai Cancer Center
Shanghai, 200032, China
Conditions
Explore the condition pages connected to this study.